5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A near-infrared probe for non-invasively monitoring cerebrospinal fluid flow by (18)F-positron emitting tomography and fluorescence
    Journal Article

    Guo, H.; Kommidi, H.; Lekaye, C. C.; Koutcher, J.; Judenhofer, M. S.; Cherry, S. R.; Wu, A. P.; Akin, O.; Souweidane, M. M.; Aras, O.; more...
    EJNMMI Research (2020)

    Fulltext@MSK | Save
  • Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting
    Editorial

    Yaeger, R.; Solit, D. B.
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Oncogenic ERG represses PI3K signaling through downregulation of IRS2
    Journal Article

    Mao, N.; Gao, D.; Hu, W.; Gadal, S.; Hieronymus, H.; Wang, S.; Lee, Y. S.; Sullivan, P.; Zhang, Z.; Choi, D.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation
    Journal Article

    Zhang, Z.; Zhou, C.; Li, X.; Barnes, S. D.; Deng, S.; Hoover, E.; Chen, C. C.; Lee, Y. S.; Zhang, Y.; Wang, C.; more...
    Cancer Cell (2020)

    Fulltext@MSK | Save
  • Depth of response (DEPOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101
    Meeting Abstract

    Voss, M. H.; Motzer, R. J.; Albiges, L.; Rini, B.I.; Schmidinger, M.; Larkin, J.; Haanen, J. B. A. G.; Kollmannsberger, C.; Campbell, M. T.; Pal, S. K.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Checkmate 214 post hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma (ARCC) with sarcomatoid features (SRCC)
    Meeting Abstract

    Grimm, M. O.; McDermott, D. F.; Choueiri, T. K.; Motzer, R. J.; Frontera, O. A.; George, S.; Powles, T.; Donskov, F.; Harrison, M. R.; Rodriguez-Cid, J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Association between depth of response (DepOR) and overall survival (OS): Exploratory analysis of nivolumab plus ipilimumab (N plus I) vs sunitinib (S) in patients with previously untreated advanced renal cell carcinoma (ARCC) in Checkmate 214
    Meeting Abstract

    Gruenwald, V.; Choueiri, T. K.; Rini, B. I.; Powles, T.; George, S.; Grimm, M. O.; McHenry, M. B.; Maurer, M.; Motzer, R. J.; Hammers, H. J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Genomic landscape of non-invasive urothelial carcinoma of the bladder
    Meeting Abstract

    Kennedy, J.; Clinton, T.; Almassi, N.; Pietzak, E.; Bochner, B.; Fine, S.; Gopalan, A.; Chen, Y. B.; Sarungbam, J.; Sirintrapun, S. J.; more...
    Laboratory Investigation (2020)

    Fulltext@MSK | Save
  • Association of KIT mutations with concurrent RAS/MAPK pathway driver alterations in seminomatous and non-seminomatous germ-cell tumors
    Meeting Abstract

    Mata, D.; Yang, S. R.; Ferguson, D.; Liu, Y.; Sharma, R.; Al-Ahmadie, H.; Solit, D.; Feldman, D.; Tickoo, S.; Reuter, V.; more...
    Laboratory Investigation (2020)

    Fulltext@MSK | Save
  • Prostate cancer with germline DNA damage repair gene alterations: A clinical and pathologic assessment
    Meeting Abstract

    Gopalan, A.; Fine, S.; Chen, Y. B.; Al-Ahmadie, H.; Sarungbam, J.; Abida, W.; Scher, H.; Tickoo, S.; Reuter, V.
    Laboratory Investigation (2020)

    Fulltext@MSK | Save